Clinical Eye Research Unit, Department of Ophthalmology, Copenhagen University Hospital Roskilde, Denmark and Faculty of Health Sciences, University of Copenhagen, Køgevej 7-13, DK-4000 Roskilde, Denmark.
BMC Ophthalmol. 2014 Feb 27;14:22. doi: 10.1186/1471-2415-14-22.
Dysregulation of the CCR3/CCL11 pathway has been implicated in the pathogenesis of choroidal neovascularisation, a common feature of late age-related macular degeneration (AMD). The aim of this study was to investigate the expression of CCR3 and its ligand CCL11 in peripheral blood in patients with neovascular AMD.
Patients with neovascular AMD and healthy controls were included. Blood samples were obtained and prepared for flow cytometry to investigate the expression of CCR3. Levels of CCL11 were measured in plasma using Cytometric Bead Array. Differences between the groups were tested using Kruskal-Wallis test and Mann-Whitney U test.
Patients (n = 83) with neovascular AMD and healthy control persons (n = 114) were included in the study. No significant difference in the expression of CCR3 was found on CD9+ granulocytes when comparing patients suffering from neovascular AMD with any of the control groups. We did not find any alteration in CCL11 levels in patients among the age matched groups. There was no correlation between expression of CCR3/CCL11 and clinical response to treatment with anti-vascular endothelial growth factor (VEGF).
Our results do not suggest a systemic alteration of the CCR3/CCL11 receptor/ligand complex in patients with neovascular AMD.
CCR3/CCL11 通路的失调与脉络膜新生血管的发病机制有关，后者是晚期年龄相关性黄斑变性（AMD）的一个常见特征。本研究旨在研究新生血管性 AMD 患者外周血中 CCR3 及其配体 CCL11 的表达。
纳入新生血管性 AMD 患者和健康对照者。采集血样并进行流式细胞术检测 CCR3 的表达，使用 Cytometric Bead Array 检测血浆中 CCL11 的水平。使用 Kruskal-Wallis 检验和 Mann-Whitney U 检验比较组间差异。
本研究纳入了 83 例新生血管性 AMD 患者和 114 例健康对照者。与任何对照组相比，CD9+粒细胞上 CCR3 的表达在患有新生血管性 AMD 的患者中没有差异。在年龄匹配的患者组中，CCL11 水平没有改变。CCR3/CCL11 的表达与抗血管内皮生长因子（VEGF）治疗的临床反应之间没有相关性。
我们的结果表明，新生血管性 AMD 患者的 CCR3/CCL11 受体/配体复合物没有全身性改变。
